Brief: Enlivex Announces The Dosing Of The First Patient In A Phase I Clinical Trial Evaluating Allocetra In Patients With Psoriatic Arthritis
14/11/2024 13:18
Nov 14 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX ANNOUNCES THE DOSING OF THE FIRST PATIENT IN A
PHASE I
CLINICAL TRIAL EVALUATING ALLOCETRA IN PATIENTS WITH PSORIATIC
ARTHRITIS
* ENLIVEX THERAPEUTICS LTD - NO SAFETY CONCERNS RECORDED
AFTER
FIRST PATIENT DOSING
* ENLIVEX THERAPEUTICS LTD - PSORIATIC ARTHRITIS TREATMENT
MARKET
PROJECTED TO REACH $20.5 BILLION BY 2032
Source text: ID:nGNXbmBcFM
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment